JPS58213765A - 新規な２−β−Ｄ−リボフラノシルセレナゾ−ル−４−カルボキサミド化合物およびそれらの製造方法 - Google Patents

新規な２−β−Ｄ−リボフラノシルセレナゾ−ル−４−カルボキサミド化合物およびそれらの製造方法

Info

Publication number: JPS58213765A
Authority: JP; Japan
Prior art keywords: selenazole; ribofuranosyl; compound; acyl; compound according
Prior art date: 1982-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP4781383A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0326194B2 (cs

Inventor

ロ−ランド・ケニス・ロビンス

プレム・チヤンドラ・スリヴアストヴア

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Brigham Young University

Original Assignee

Brigham Young University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-23

Filing date

1983-03-22

Publication date

1983-12-12

1983-03-22 Application filed by Brigham Young University filed Critical Brigham Young University

1983-12-12 Publication of JPS58213765A publication Critical patent/JPS58213765A/ja

1991-04-10 Publication of JPH0326194B2 publication Critical patent/JPH0326194B2/ja

Status Granted legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 title claims description 3
CKMBACZHCFMPLQ-DBRKOABJSA-N 2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-selenazole-4-carboxamide Chemical class NC(=O)C1=C[se]C([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 CKMBACZHCFMPLQ-DBRKOABJSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 100
239000000203 mixture Substances 0.000 claims description 32
241001465754 Metazoa Species 0.000 claims description 31
238000000034 method Methods 0.000 claims description 30
201000011510 cancer Diseases 0.000 claims description 16
125000002252 acyl group Chemical group 0.000 claims description 15
239000011669 selenium Substances 0.000 claims description 15
239000002253 acid Substances 0.000 claims description 14
125000000217 alkyl group Chemical group 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 14
238000006243 chemical reaction Methods 0.000 claims description 13
230000000840 anti-viral effect Effects 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 12
-1 furanosyl cyanide Chemical compound 0.000 claims description 12
125000003843 furanosyl group Chemical group 0.000 claims description 11
125000003710 aryl alkyl group Chemical group 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 7
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
229910052711 selenium Inorganic materials 0.000 claims description 6
239000007858 starting material Substances 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
SPVXKVOXSXTJOY-UHFFFAOYSA-N selane Chemical compound [SeH2] SPVXKVOXSXTJOY-UHFFFAOYSA-N 0.000 claims description 5
229910000058 selane Inorganic materials 0.000 claims description 5
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
208000036142 Viral infection Diseases 0.000 claims description 4
230000000259 anti-tumor effect Effects 0.000 claims description 4
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
239000003054 catalyst Substances 0.000 claims description 4
230000009385 viral infection Effects 0.000 claims description 4
241001474791 Proboscis Species 0.000 claims description 3
238000005917 acylation reaction Methods 0.000 claims description 3
238000005915 ammonolysis reaction Methods 0.000 claims description 3
238000006642 detritylation reaction Methods 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 3
241001660687 Xantho Species 0.000 claims description 2
230000010933 acylation Effects 0.000 claims description 2
239000003292 glue Substances 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
238000006366 phosphorylation reaction Methods 0.000 claims description 2
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 claims 2
230000001815 facial effect Effects 0.000 claims 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
239000010931 gold Substances 0.000 claims 1
229910052737 gold Inorganic materials 0.000 claims 1
230000026731 phosphorylation Effects 0.000 claims 1
230000000865 phosphorylative effect Effects 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
206010028980 Neoplasm Diseases 0.000 description 21
239000000047 product Substances 0.000 description 21
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 17
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
238000012360 testing method Methods 0.000 description 14
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
241000700605 Viruses Species 0.000 description 13
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
239000003814 drug Substances 0.000 description 10
229940125904 compound 1 Drugs 0.000 description 8
229940079593 drug Drugs 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
238000009472 formulation Methods 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
239000002904 solvent Substances 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
239000010410 layer Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
239000002246 antineoplastic agent Substances 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
159000000000 sodium salts Chemical class 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
239000006188 syrup Substances 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
150000003857 carboxamides Chemical class 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000003127 knee Anatomy 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
ODIRBFFBCSTPTO-UHFFFAOYSA-N 1,3-selenazole Chemical compound C1=C[se]C=N1 ODIRBFFBCSTPTO-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010070863 Toxicity to various agents Diseases 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
241000701242 Adenoviridae Species 0.000 description 1
241001289384 Beloniformes Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
244000175448 Citrus madurensis Species 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
241000252233 Cyprinus carpio Species 0.000 description 1
235000017317 Fortunella Nutrition 0.000 description 1
KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
241000700586 Herpesviridae Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
239000005643 Pelargonic acid Substances 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000702247 Reoviridae Species 0.000 description 1
241000711931 Rhabdoviridae Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
108700010877 adenoviridae proteins Proteins 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003796 beauty Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
229960004830 cetylpyridinium Drugs 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
210000001726 chromosome structure Anatomy 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000004020 conductor Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
239000012351 deprotecting agent Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
125000005131 dialkylammonium group Chemical group 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000011363 dried mixture Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000003255 drug test Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000010828 elution Methods 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
230000002977 hyperthermial effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000000155 melt Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000012149 noodles Nutrition 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
IOQPZZOEVPZRBK-UHFFFAOYSA-O octylazanium Chemical compound CCCCCCCC[NH3+] IOQPZZOEVPZRBK-UHFFFAOYSA-O 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
GSWAOPJLTADLTN-UHFFFAOYSA-N oxidanimine Chemical compound [O-][NH3+] GSWAOPJLTADLTN-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
238000000746 purification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000002940 repellent Effects 0.000 description 1
239000005871 repellent Substances 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
208000011581 secondary neoplasm Diseases 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000002893 slag Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
230000003068 static effect Effects 0.000 description 1
101150035983 str1 gene Proteins 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
125000005208 trialkylammonium group Chemical group 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
238000005866 tritylation reaction Methods 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
229940005605 valeric acid Drugs 0.000 description 1
230000003253 viricidal effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Landscapes

Furan Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP4781383A 1982-03-23 1983-03-22 新規な２−β−Ｄ−リボフラノシルセレナゾ−ル−４−カルボキサミド化合物およびそれらの製造方法 Granted JPS58213765A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US36096882A	1982-03-23	1982-03-23
US465221		1983-02-15
US360968		1989-06-02

Publications (2)

Publication Number	Publication Date
JPS58213765A true JPS58213765A (ja)	1983-12-12
JPH0326194B2 JPH0326194B2 (cs)	1991-04-10

Family

ID=23420119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP4781383A Granted JPS58213765A (ja)	1982-03-23	1983-03-22	新規な２−β−Ｄ−リボフラノシルセレナゾ−ル−４−カルボキサミド化合物およびそれらの製造方法

Country Status (2)

Country	Link
JP (1)	JPS58213765A (cs)
ZA (1)	ZA832003B (cs)

1983
- 1983-03-22 JP JP4781383A patent/JPS58213765A/ja active Granted
- 1983-03-22 ZA ZA832003A patent/ZA832003B/xx unknown

Also Published As

Publication number	Publication date
ZA832003B (en)	1983-11-30
JPH0326194B2 (cs)	1991-04-10

Publication	Publication Date	Title
EA038192B1 (ru)	2021-07-21	Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение
EP0417941B1 (en)	1995-11-08	Use of a cyanine dye in an antitumor agent
CN105732381B (zh)	2021-07-20	牛樟芝提取物及其制备方法和应用
JP2007535525A (ja)	2007-12-06	β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
CN102596220A (zh)	2012-07-18	单磷酸化的脂质a衍生物
JPH01157995A (ja)	1989-06-21	鎮痛−抗炎症活性を有するガングリオシドの内部エステル
JP2919867B2 (ja)	1999-07-19	抗腫瘍剤
CN101579478A (zh)	2009-11-18	中药复方五子抵瘤抗肿瘤活性有效部位组合物及其制备方法
CN1308000C (zh)	2007-04-04	用于治疗实体瘤的含有白头翁根浸膏作为活性成分的药物
JP6389958B2 (ja)	2018-09-12	瓦草５環性トリテルペンサポニン類化合物抗腫瘍の薬物用途
Parker et al.	1978	N-Trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies
US4531001A (en)	1985-07-23	2-β-D-ribofuranosylselenazole-4-carboxamide compounds
JPS58213765A (ja)	1983-12-12	新規な２−β−Ｄ−リボフラノシルセレナゾ−ル−４−カルボキサミド化合物およびそれらの製造方法
US5710179A (en)	1998-01-20	Antitumor agent
WO2005116042A1 (en)	2005-12-08	Treatment and prevention of cancer with new ginsenoside derivatives
JP2001527569A (ja)	2001-12-25	ウスカリジンまたはその類似体を含有する医薬組成物
JP4130700B2 (ja)	2008-08-06	抗腫瘍剤含有組成物
EP0054432B1 (en)	1990-01-31	Use of 2-beta-d-ribofuranosylthiazole-4-carboxamides for the manufacture of medicaments inhibiting malignant tumors
CN119235877B (zh)	2025-11-11	一种钌(iii)酸盐的组合物及其应用
US4594416A (en)	1986-06-10	2-β-D-ribofuranosylselenazole-4-carboxamide compounds and methods for their production
US4594414A (en)	1986-06-10	2-β-D-ribofuranosylselenazole-4-carboxamide compounds and methods for their production
US4835176A (en)	1989-05-30	Glycookadaic acid, preparation thereof and use thereof
JPH0427965B2 (cs)	1992-05-13
KR20050117501A (ko)	2005-12-14	진세노사이드 유도체의 제조방법
JP3793602B2 (ja)	2006-07-05	ステロイド配糖体及びこれを有効成分とする医薬